BACKGROUND: Pediatric participants on phase 1 or phase 2 clinical trials for incurable cancer are at risk of experiencing toxicities (adverse events [AEs]) related to trial participation. Multiple AEs are subjective; thus, the real impact of trial treatment cannot be known unless patient subjective reports are solicited. METHODS: The authors assessed the feasibility and acceptability of soliciting symptom, function, and quality of life (QOL) reports from participants aged 8 to 18 years who were enrolled on phase 1/2 clinical trials at 4 cancer centers during the first course of chemotherapy. The authors also assessed the reliability and validity of 6 self-report Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures and 4 open-ended interview questions at 2 time points (at the time of trial enrollment [T1] and 3 to 4 weeks later [T2]). RESULTS: The enrollment rate of 75.9% (20 participants) exceeded the feasibility criterion, and missingness of measures by person, measure, and items at T1 and T2 were lower than the acceptability criteria. New QOL themes were limited to the impact of treatment on families and being away from home, family, and friends for treatment. All but one measure at T1 met the reliability criterion and all measures did so at T2. Validity support was limited however because as theorized, mobility decreased and fatigue increased as AEs increased. CONCLUSIONS: Soliciting and documenting symptom, function, and QOL reports from patients aged 8 to 18 years who are enrolled on a phase 1/2 clinical trial is feasible and acceptable to participants, particularly when embedded in trials. Reliable and valid findings can result, making patient self-reported outcomes a possible new trial endpoint.
INTRODUCTION
In the United States, cancer is the number 1 disease-related cause of death in children aged 1 to 19 years 1 ; approximately 25% of the 12,400 children newly diagnosed with cancer will die of their disease. 2 A priority of the National Cancer Institute, the National Institute of Nursing Research, and professional groups is to improve the quality of life (QOL) of pediatric patients with incurable cancer. [3] [4] [5] Measuring these patients' symptom and QOL reports or patient-reported outcomes (PROs) will help clinicians to better anticipate and manage symptoms and thereby reduce patient and family suffering. PROs are included in those therapeutic trials in which the objective is cure. 3, [6] [7] [8] It is exceedingly rare for PROs to be incorporated into pediatric phase 1 or phase 2 trials, although these trials contribute to new drug indications and labeling. The US Food and Drug Administration has released guidance concerning the use of PROs in trials to support drug labeling, including language requiring PROs in pediatrics. [9] [10] [11] To our knowledge to date, no pediatric oncology drug indication has been secured on the basis of PROs.
Experimental drug trials collect information regarding organ and system treatment-related adverse events (AEs) but not the child's report of symptom or function AEs. Two recent reports of pediatric phase 1/2 trials included a generic QOL measure, but symptom and function PROs specific to the impact of the study treatment were not solicited. 12, 13 Failure to include these PROs means that children and adolescents enrolled on phase 1/2 clinical trials who are very likely to experience AEs [14] [15] [16] [17] [18] are not systematically asked to report on their symptoms or functioning while enrolled on the trial. Minus these patient reports, the full impact of the treatment on the patient is likely underreported and thereby undermanaged.
Using PRO measures, children as young as 8 years can reliably report on the majority of aspects of their health status, and younger children have reliably reported on selected health domains using paper-based or computer-based methods. 7, 8, [19] [20] [21] Because cancer clinical trials have longitudinal designs, pediatric self-report measures must be able to capture statistically significant and clinically meaningful changes or minimally important differences (MIDs) in PROs. A MID is the smallest difference in scores reported as beneficial (improvement) or harmful (deterioration) and requires a change in treatment. 22, 23 The Patient-Reported Outcomes Measurement Information System (PROMIS) initiative sponsored by the National Institutes of Health Roadmap for Medical Research developed and validated instrumentation to measure symptoms, function, and other aspects of QOL by patient report among patients with cancer who were aged 8 to 18 years. 24, 25 In the current study, these measures in combination with an interview allowed us to go beyond the traditionally measured benefit of phase 1/2 trial participation by children and adolescents with incurable cancer (tumor response) to measuring their symptoms, function, and QOL.
The objectives of the current study were to demonstrate the feasibility and acceptability of completing PROMIS pediatric measures by children enrolled on a phase 1/2 trial at 2 data points at which we anticipated clinical changes (at the time of trial enrollment [T1] and 3 to 4 weeks later [T2]). In this longitudinal validity study involving patients aged 8 to 18 years with incurable or refractory cancer who were enrolled on phase 1/2 trials, we had 2 objectives: 1) to assess the feasibility (enrollments and study refusals) and acceptability (attrition and unanswered measures or items) of the PROMIS pediatric measures among participants; and 2) to develop initial estimates of the reliability, validity, responsiveness, and range of the MIDs of the PROMIS pediatric measures in this population.
The current study framework was the theory of unpleasant symptoms, 26, 27 which posits that symptom characteristics (duration, quality, distress, and intensity) and their outcomes are influenced by physiologic, psychological, and situational factors. Given our anticipated limited sample size, we did not test the framework but assessed theoretically derived, previously supported relationships [6] [7] [8] as validity assessments of the PROMIS measures in this patient group (eg, higher fatigue is associated with higher toxicity).
MATERIALS AND METHODS
We used a pre-post design and qualitative and quantitative methods to solicit patient reports. We recruited children and adolescents enrolled on a phase 1/2 trial at 4 cancer settings: 1) Children's National Health System in Washington, DC; 2) Seattle Children's Hospital; 3) Children's Hospital of Philadelphia; and 4) Boston Children's Hospital.
Inclusion Criteria
Eligible children had a cancer diagnosis, were aged 8 to 18 years, were able to speak and read English, were enrolled on a phase 1/2 trial because of advanced cancer for which no curative therapy existed, and were able to manipulate a computer mouse for responding to computer-adaptive test items.
Exclusion Criteria
Patients were excluded if the parent or child refused participation.
Study Procedures
Patients were recruited during an inpatient or outpatient visit after enrollment in a phase 1/2 trial. If the parents provided permission to approach their child regarding the study, the team member explained the study to the child. Parent and child refusals and agreements were documented. Participants were given a study identification number and completed the PROMIS measures using a private clinic/hospital room computer or laptop.
Study Measures
PROMIS pediatric measures at T1 and T2 PROMIS pediatric measures document child and adolescent reports of their symptom and function experiences with illness and treatment. We administered the 6-item short-form measures for the scales of Mobility, Pain, Fatigue, Depressive Symptoms, Anxiety, and Peer Relationships as previously administered via computer in a cross-sectional, National Institutes of Health-supported study. 24 
QOL interview questions for T2
We asked participants open-ended interview questions previously used with patients with cancer who were aged 8 to 18 years regarding their QOL while receiving chemotherapy 28 and 2 additional questions (questions 3 and 4) that addressed acceptability.
Demographic and clinical information
Demographic (at T1) and clinical information (at T1 and T2) were collected for each patient participant. Clinical information was comprised of diagnosis and toxicity reports, with the latter routinely measured at each visit by clinician report using the Common Terminology Criteria for Adverse Events (CTCAE) reporting form. 29 
Statistical Analysis
Preliminary data were analyzed using descriptive and graphical methods. All item response variables were examined using measures of central tendency (mean), spread (standard deviation), and response category frequencies. Composite measures were used for all the PROMIS measures in validity and responsiveness tests.
We documented the number of parents who agreed to have their child invited to the study and those who declined. We also documented reasons for agreement and refusal as per standard methods. 30 We considered feasibility and acceptability to be achieved if the rate of enrollment was 70%, if attrition was 15%, and if missingness was less than or similar to that of previous palliative care studies. 6, 31, 32 We also used descriptive statistics to assess missingness by PROMIS measure, participant, item, and time point.
The interview responses from the open-ended questions were analyzed using a semantic (theme or meaningbased) content analytic technique with coding and interrater reliability assessments using Krippendorff strategies. 33, 34 We considered rater agreement (involving 2 raters) to be achieved at a level 90%. Resulting themes were compared with the PROMIS measures to assess whether new QOL domains emerged.
The reliability of the PROMIS measures at T1 and T2 was assessed using the Cronbach a. Information regarding AEs (type, grade, and attribution) for each participant was extracted from the CTCAE, with all AEs reported as per the primary treatment study guidelines and inclusive of the T1 and T2 dates. If an AE occurred multiple times during the course of the study, only the highest grade for the longest duration was included in the analysis. The majority of the clinical trials used version 4.0 of the CTCAE, and all but 1 trial used the 5-point attribution scale. The difference in the mean scores of the PROMIS measures by the number of AEs (>8 or 8) was used to examine the criterion validity of the PROMIS measures. Because the sample size in the current study was small (20 participants), a bootstrap approach 35 was applied for estimating the Cronbach a with standard error and testing validity of each PROMIS measure. Bootstrapping was performed based on 1000 resamples randomly drawn from the original sample without replacement.
Internal responsiveness (ability of a measure to change) was examined using: 1) the Student t test for paired data to assess the difference in PROMIS mean scores between T1 and T2; 2) effect size I (ESI), relating the average change in outcome between T1 and T2 to the variability in baseline scores; and 3) effect size II (ESII), relating the average change in outcome between T1 and T2 to the variability in change scores. 36, 37 We considered the magnitude of effect sizes <0.2, 0.2 to 0.49, 0.5 to 0.79, and >0.8 as negligible, small, moderate, and large, respectively. 38 In addition, the smallest real difference (SRD) (the 95% confidence limit of the standard error of the difference scores) also was used to assess sensitivity to change. 39 For individuals, the change score of each PROMIS measure was compared with the corresponding SRD. When the change exceeded the SRD, it was assumed that a real change occurred that was not attributable to "noise." We also applied the established, patientbased MID score of a 3-point difference (63 points) in PROMIS measures to represent important score differences between the 2 data points. 40 
RESULTS

First Study Objective
With regard to the first objective of the current study, a total of 29 patients met eligibility criteria during the 20 months of screening at the 4 study sites; 5 parents declined and 2 patients declined to participate, with the remaining 22 patients agreeing to participate (75.9% enrollment rate). Of these, 20 patients (90.9%) participated at T1 and 17 patients (77.3%) participated at T2. The majority of patients were male, adolescent, and white (Table 1) and had a solid tumor (13 patients). Ten protocols were represented; 7 participants were enrolled on the same phase 1 trial that was open at all 4 sites in which the PRO measures were embedded. The time to complete study measures at T1 ranged from 11 to 20 minutes and that at T2 ranged from 24 to 30 minutes because the interview questions occurred at T2.
PROMIS measure missingness at T1 was limited to 1 patient not completing 2 measures and 2 patients not completing 1 measure, for an overall rate of person missingness of 15% and a measure missingness rate of 3.3%. The PROMIS person missingness at T2 (2 patients not completing 1 measure each) was 11.8% and the measure missingness rate (2 persons not completing the peer relationship measure) was 2%. Individual item missingness at T1 was 1 pain item (0.14%) and at T2 was 7 items (1.1%) across 4 different measures (4 items not answered by the same participant).
Coder agreement for the interview questions exceeded the 90% level. The most frequent responses to interview question 1 ("a good day") from 15 participants (88.2%) indicated favorable reactions to the
new study drug, including fewer side effects and life interruptions than when receiving the frontline treatment. In response to the "bad day" question, 7 participants (41.2%) reported AEs and 5 (29.4%) reported having to accommodate the protocol in terms of scheduled medication times and other interruptions to usual activities. Three patients reported being uneasy concerning the possible meaning of the pain they were experiencing. In response to the question about "any surprises," 16 participants (94%) indicated that the experimental treatment was without surprises. Six participants (35%) described not liking to be at the hospital because it took valuable time away from family and friends (Table 2) .
Six participants wanted physicians and nurses to know that being on the trial was an overall positive experience, whereas 3 other participants noted the inconvenience of following the protocol guidelines and uneasiness about waiting to learn of the treatment outcomes. Twelve participants indicated the PROMIS items captured what was important and 3 reported that the items were repetitive and too numerous. Six participants suggested that items be added regarding being away from home, family, and friends and the impact of treatment on family members; 2 recommended more items regarding anger and other feelings, 1 recommended items concerning appetite, and 2 recommended items regarding how to answer questions that others posed to them about their illness (data not shown).
Second Study Objective
Bootstrap estimates of the Cronbach a by PROMIS measure at T1 indicated that 5 of 6 measures had an a value greater than the accepted cutoff point of 0.70 (Peer Relationships was found to be slightly lower at 0.69). The a values were acceptable for all measures at T2 ( Table 3) . The results of the Student t test for paired data and responsiveness indices (ESI, ESII, and SRD) indicated that average changes in the measures from T1 to T2 were small, and none of the corresponding results from the Student t test for paired data were found to be statistically significant ( Table 4 ). The percentage of patients reaching the SRD criterion was low for all the scales, ranging from 5.3% (Depression, Anxiety, Fatigue, and Mobility) to 15.8% (Peer Relationships).
The number of AEs per participant from the CTCAE forms ranged from 0 to 23, with 7 participants having >8 AEs and 12 reporting <8 AEs. As theorized, mobility was significantly worse as the number of AEs increased, and as the number of AEs increased, fatigue was worse at both time points, although this did not reach statistical significance (Table 5 ). Using the patient-based MID value of 63 change between the time points, 9 patients had MID changes in anxiety (6 had improvements), 10 had MID changes in depression (7 had improvements), 9 had MID changes in fatigue (3 had improvements), 9 had MID changes in mobility (4 had improvements), 9 had MID changes in pain (4 had improvements), and 10 had MID changes in peer relationships (7 had improvements).
DISCUSSION
The current study allowed us to measure in a standardized approach the symptom and function reports of children and adolescents enrolled on phase 1/2 cancer trials during the first course. In addition, using interviews, we solicited what aspects of symptoms and QOL were most important to these patients at this point in their lives and cancer treatment. Our enrollment findings indicated that it is feasible to solicit PROs directly from participating children and adolescents because our enrollment rate (75.9%) exceeded our defined acceptable rate (70%). Refusals to enroll were more likely to come from parents (17.2%) than the eligible patients (8.3%), and only occurred when the self-report measures were not embedded in the clinical trial. Four of the 5 parents refusing participation expressed reluctance to experience an additional consent process. Our attrition rate (15%) met our goal of 15% and also supported feasibility. Acceptability to the participants also was assessed using missingness of data by person, measure, and items. The number of patients not completing a PROMIS measure in this study (15% at T1 and 11.8% at T2) was somewhat higher than the rate of 8% noted in our previous study during or after cure-oriented cancer treatment. 24 However, measure missingness rates in the current study at T1 (3.3%) and T2 (2%) were lower than in the crosssectional study (9.5%), as was individual item missingness (0.14% at T1 and 1.1% at T2). 22, 41 It is important to note that these findings support the feasibility and acceptability of completing quantitative and qualitative measures regarding their symptom, function, and QOL Please share with me how being on this new study and its medication has been for you (any surprises?)? (n 5 16)
Being on study is positive The new treatment is more convenient and manageable than conventional chemotherapy (fewer side effects) and may affect the disease
14/7
Not experiencing any surprises on the study Being on the new protocol was without unexpected events 13/9
Loathing time needed for treatment Not liking to be at the hospital as care takes valuable time away from family and friends
11/6
What else is important for your doctors and nurses to know about what it is like for you to be on this study medication? (n 5 15) experiences among children and adolescents with incurable cancer while enrolled on a phase 1/2 clinical trial. We also documented through interviews the ability of children and adolescents to speak to their overall QOL while enrolled on an early-stage trial. The 16 respondents to the interview questions indicated that, for the most part, being on the study was not as demanding as taking part in frontline therapy protocols. One participant acknowledged worrying whether the drug was effective but emphasized having no regrets about participating. Approximately one-half of participants described AEs that occasionally prevented them from engaging in preferred activities. Approximately one-half of the participants also indicated the items on the PROMIS measures represented what was important to them; others suggested additions regarding sports, appetite, the impact of treatment on family, and being away from home. In summary, the PROMIS measures used in the current study appear to have captured most of what was important to children and adolescents enrolled on a phase 1/2 clinical trial for incurable cancer with the exception of the impact of treatment on family and time with family and friends.
To the best of our knowledge, the current study represents the first time that the PROMIS pediatric measures have been completed by children and adolescents with incurable cancer who are taking part in a phase 1/2 clinical trial. It is important to note that the internal consistency estimates indicate that the measures were reliable at both time points in this patient group. Estimates of validity are more limited in the study findings, a fact that most likely is related to the small sample size, although as theorized, mobility was statistically significantly better at both data points when fewer AEs were experienced. A similar trend was noted for fatigue, with lower rates of fatigue associated with fewer AEs.
Important study limitations exist, particularly the small sample size, which influenced validity tests. The 20 months needed to identify 29 eligible participants across the 4 study settings conveys the need to include sufficient settings in a future extension of this work. Another limitation is the parent refusal rate, in which 4 of 5 refusing parents attributed their declining to participate to not wanting to experience a second consent process after Abbreviations: >8 Events, total number of adverse events >8; 8 Events, total number of adverse events 8; AE, adverse event; Diff, mean difference between groups was tested using Student t test based on 1000 bootstrap resamples; PROMIS, Patient-Reported Outcomes Measurement Information System; SD, standard deviation.
completing the clinical trial consent process. There were no parent or child refusals when the PROs were embedded. We recommend that future pediatric oncology phase 1/2 trials embed PROs and allow age-eligible participants to choose whether to complete the embedded measures. Embedded PROs can be examined in relation to clinical and disease variables, making them more clinically interpretable. Embedding also will allow pediatric oncology clinicians to better understand the full impact of novel therapies and to minimize or prevent likely toxicities. The results of the current study confirm the feasibility and acceptability of soliciting and documenting these endpoints in pediatric oncology phase 1/2 clinical trials.
Conclusions
Only by measuring and understanding self-reported symptoms and function in children and adolescents with incurable cancer can we adequately address threats to their QOL and improve symptom control and supportive care. By embedding PROs such as PROMIS in experimental clinical trials, we provide voice to enrolled children and adolescents to inform clinicians about their subjective treatment experiences.
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